FDA Grants Fast Track to Elticertinib for Heavily Pretreated EGFR Exon 20 NSCLC

Laboratoires Pierre Fabre announced on Monday that the U.S. Food and Drug Administration has granted Fast Track designation to elticertinib for adults with locally advanced or metastatic non-small cell lung cancer harboring EGFR exon 20 insertion mutations whose disease has progressed on both platinum-based chemotherapy and amivantamab.

The designation, disclosed in a company news release, is based on nonclinical data and preliminary efficacy results from the ongoing Phase 1/2 trial NCT06043817. It gives the French pharmaceutical company more frequent interaction with the FDA and makes the drug eligible for rolling and priority review if criteria are met, according to PRNewswire.

Elticertinib, an oral, irreversible, highly selective tyrosine kinase inhibitor targeting EGFR and HER2 exon 20 insertion mutations, is being developed for a heavily pretreated population that currently has few options.

“This designation underscores the urgent need for new treatment options for patients with EGFR ex20ins-mutated NSCLC, who still face limited efficacy and significant tolerability challenges with currently available therapies,” said Marie-Andrée Gamache, Pharma Chief Executive Officer of Laboratoires Pierre Fabre, in the release.

FDA Grants Fast Track to Elticertinib for Heavily Pretreated EGFR Exon 20 NSCLC
Photo: finance.yahoo.com

The situation for this mutation has changed in recent years. Amivantamab, a bispecific antibody targeting EGFR and MET, received FDA approval in combination with carboplatin and pemetrexed as first-line treatment based on the phase 3 PAPILLON trial, which showed improved progression-free survival versus chemotherapy alone, Targeted Onc reported.

In July 2025, the FDA granted accelerated approval to the oral TKI sunvozertinib (Zegfrovy) for patients whose disease progressed on or after platinum-based chemotherapy; the phase 2 WU-KONG1B study showed a confirmed objective response rate of 46 percent with a median duration of response of 11.1 months at the approved 200-mg dose.

“This fast-track designation is a first for Laboratoires Pierre Fabre, and a significant milestone that reflects the strength and maturity of our R&D capabilities in oncology.”

“This fast-track designation is a first for Laboratoires Pierre Fabre, and a significant milestone that reflects the strength and maturity of our R&D capabilities in oncology,” said Eric Ducournau, Chief Executive Officer of Laboratoires Pierre Fabre. He added that it confirms the company’s ability to bring innovative, highly differentiated therapies from research to patients and strengthens its ambition to become a recognized global player in precision oncology.

EGFR mutations are the most frequent drivers of NSCLC, occurring in up to 38 percent of tumors depending on geography, and up to 10 percent of those carry exon 20 insertions, according to the company’s release carried by PRNewswire. Elticertinib aims to address the gap after both chemotherapy and amivantamab fail, a space where sunvozertinib was approved but where tolerability and durability remain concerns.

The company plans to continue advancing elticertinib through clinical development, with additional data needed to establish its potential in this setting. The Phase 1/2 trial NCT06043817 remains ongoing.